阿尔茨海默病患者死后脑样本中的脂质介质:系统性审查
Aidan D Tyrrell1, Giulia Cisbani1, Mackenzie E Smith1
1Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Canada.
Brain, behavior, & immunity - health
|February 3, 2025
概括
阿尔茨海默病 (AD) 中的神经炎症涉及改变的脂质介质. 在阿尔茨海默氏症大脑中,促炎性脂质增加,而抗炎性脂质减少,这表明在疾病病理学中发挥了作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 病理与神经炎症有关,由和β-粉样蛋白驱动.
- 大脑中的脂质介质调节失调可能会在阿尔茨海默病患者中促进这种炎症反应.
研究的目的:
- 系统地审查有关阿尔茨海默病大脑中的脂质介质及其相关酶的文献.
- 确定多不和脂肪酸衍生的脂质介质在AD相关的神经炎症中的作用.
主要方法:
- 在Medline,Embase和PsychINFO的系统文献搜索,截至2024年4月22日.
- 将测量脂质介质或生产酶的研究纳入来自AD患者和对照者的死后脑样本中的研究.
- 分析了50项相关研究,重点关注已识别的脂质媒介和酶水平.
主要成果:
- 在AD大脑中,促炎性脂质介质 (例如,氧酸酸,前列腺素D2) 升高.
- 在AD大脑中,抗炎性脂质调解剂 (例如,脂素A4,DHA衍生的多可沙诺酸) 的含量下降.
- 酶水平显示出一种趋势,即增加了诸如循环氧化酶 (COX) 和脂氧化酶 (LOX) 等促炎酶的表达.
结论:
- 研究结果支持神经炎症参与阿尔茨海默病的发病过程,如脂质媒介所示.
- 单个脂质代谢物和酶对AD进展的确切贡献仍需要阐明.
- 需要进一步的研究来澄清这些分子在阿尔茨海默病中的具体作用.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35